Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB February 26, 2026 1:00 PM ...

Adjusted gross margin is expected to land between 45% and 47%. Adjusted EBITDA is anticipated to be between $135 million to $155 million. Net income is expected to be between a loss of $30 million and ...

Q4 2025 earnings call: revenue, free cash flow, 2026 guidance, AI strategy, Uber integration and moats—read the key takeaways now.

Consolidated revenue grew 12%, supported by meaningful gross margin expansion and stronger double-digit growth in adjusted EBITDA and operating cash flow. That momentum continued through the fourth ...

Allegion demonstrates consistent revenue per share growth, expanding margins, and consistent dividend increases. Read here ...

The Education Technology Services (ETS) segment grew revenue by more than 40% to nearly $150 million for the year, with operating income increasing 38% to $59 million and an operating margin of 40%.

Stephen Willey, Stifel, focused on Niktimvo's sequential growth and biological rationale for IPF expansion. Closter cited strong persistency and account engagement, while Botwood emphasized ...

IPO, but Figure’s blockchain lending platform is expanding into mortgages and auto loans—see the bullish case and buy-the-dip ...

We're transitioning from building a pipeline to building a business." He highlighted the successful launch of PALSONIFY as the company's first commercial product and emphasized its label reflecting ...

Recent Meta deal and expanded India partnership underscore AMD's rising competitiveness against Nvidia and Broadcom in AI ...

SSE looks overvalued despite strong gains. Explore the £33bn capex, rising debt, EPS targets and weak dividend yield—read ...

Q4 2025 earnings call recap: broadband churn trends, ARPU outlook, mobile launch, MBI deal, and free cash flow metrics—read now.